Bromazolam Stats & Data

Bromazolam was first synthesized in 1976 as part of benzodiazepine research, representing a structural modification of alprazolam where the chlorine atom is replaced with bromine. Despite its early synthesis, the compound was never developed as a pharmaceutical product or brought to market for medical use. The substance remained largely obscure until it emerged in the designer drug market decades later. In 2016, bromazolam was definitively identified by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) after appearing in Sweden, marking its entry into the novel psychoactive substances landscape. Since then, it has become one of the more prevalent novel benzodiazepines in circulation. In parts of North America, particularly Canada, bromazolam has become intertwined with the illicit opioid supply. Street-level products combining bromazolam with opioids such as heroin or fentanyl analogues have emerged, sometimes referred to colloquially as "benzo-dope." This adulteration pattern has raised significant public health concerns due to the compounded risks of combining central nervous system depressants.

Effects aggregated from 4 experience reports (4 Erowid)

Most common forms and preparations reported